Overview

Open Label Study of DS-5573a

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.